PharmacyCodes



Moclobemidum [Inn-Latin] en es it fr

Moclobemidum [Inn-Latin] Brand names, Moclobemidum [Inn-Latin] Analogs

Moclobemidum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Moclobemidum [Inn-Latin] Chemical_Formula

C13H17ClN2O2

Moclobemidum [Inn-Latin] RX_link

No information avaliable

Moclobemidum [Inn-Latin] fda sheet

Moclobemidum [Inn-Latin] msds (material safety sheet)

Moclobemidum [Inn-Latin] Synthesis Reference

No information avaliable

Moclobemidum [Inn-Latin] Molecular Weight

268.739 g/mol

Moclobemidum [Inn-Latin] Melting Point

No information avaliable

Moclobemidum [Inn-Latin] H2O Solubility

No information avaliable

Moclobemidum [Inn-Latin] State

Solid

Moclobemidum [Inn-Latin] LogP

1.298

Moclobemidum [Inn-Latin] Dosage Forms

Tablet

Moclobemidum [Inn-Latin] Indication

For the treatment of depression.

Moclobemidum [Inn-Latin] Pharmacology

Moclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.

Moclobemidum [Inn-Latin] Absorption

No information avaliable

Moclobemidum [Inn-Latin] side effects and Toxicity

No information avaliable

Moclobemidum [Inn-Latin] Patient Information

No information avaliable

Moclobemidum [Inn-Latin] Organisms Affected

Humans and other mammals